Syncona led a £63.5m Series B round in Resolution Therapeutics.

Syncona, a healthcare company, led a £63.5m Series B round in Resolution Therapeutics, a clinical-stage biopharmaceutical company. "As we prepare to advance RTX001, our lead investigational macrophage therapy with first-in-class potential for the treatment of end-stage liver disease, into the clinic this year, we are grateful for Syncona's continued support," Amir Hefni, Resolution CEO.